The present study shows that supaglutide dose-dependently stimulates insulin secretion in both mouse and human islets, and that supaglutide therapy over prolonged periods of time (twice a week injection for 4-weeks) results in an overall improvement in glycemic control, amelioration of obesity and improving lipid metabolism in hyperglycemic obese db/db mice. Here, INS is linked to obesity disorder.